MedTrace Logo

Impact of Psychological Therapies on Emergency Medical Patients

NCT05303870 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2022-07-27

No results posted yet for this study

Summary

Prevalence of anxiety and depression in the general population is known, but is under researched in the acute hospital setting and there is little evidence on the prevalence of anxiety and depression within the emergency medical admission population. A potential intervention for treating such mental health prevalence would be in the form of IAPT methodology which has been utilised in other parts of the NHS demonstrating good outcomes. Therefore, this feasibility study will explore the utility of IAPT in the acute setting.

This study will explore the prevalence of anxiety and depression in the emergency medical population within medical inpatient wards , utilising the assessment tools adopted by the IAPT services and explained in detail below.

The study will explore a) feasibility of introducing psychological intervention to an emergency medical ward and b) provide preliminary data on the outcome of this intervention on hospital length of stay and readmission rates.

Conditions

  • Mental Health Disorder
  • Mental Disorder
  • Mental Health Wellness 1

Interventions

OTHER

Improving access to psychological therapies (IAPT)

IAPT services provide evidence-based treatments for people with depression and anxiety disorders, and comorbid long-term physical health conditions or medically unexplained symptoms. IAPT services are characterised by three key principles: 1. Evidence-Based psychological therapies at the appropriate dose: NICE recommended therapies matched to the mental health problem, at the intensity and duration designed to optimise outcomes. 2. Appropriately trained and supervised workforce. 3. Routine outcome monitoring.

Sponsors & Collaborators

  • University of Essex

    collaborator OTHER

  • East Suffolk and North Essex NHS Foundation Trust

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-10-10
Primary Completion
2022-03-27
Completion
2022-03-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05303870 on ClinicalTrials.gov